[Growth hormone in children and adolescents with cystic fibrosis].
The recombinant human growth hormone (rhGH) can improve weight gain, physical growth, clinical and lung in cystic fibrosis (CF). However, the routine use, although promising, is not established in the literature. The objective of this study was to assess the benefits of rhGH in children and adolescents with CF. We conducted a systematic review in the database PubMed, Lilacs, SciELO and Cochrane, in the period 2000-2010, using the keywords: "cystic fibrosis", "growth hormone", "children" and "adolescents". We found 77 articles and included 11 randomized controlled trials, with 290 children and adolescents with CF. The short-term use (1-24 months) of rhGH improved the height, weight, growth rate, bone mineral content and components of pulmonary function. Adverse effects, like diabetes, were not observed in the studies. The short-term use of rhGH improved growth and body composition in patients with CF.
Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brasil. pollyanag@gmail.com
Pollyana Garcia
PG
Amorim
Thaís de Barros
Tde B
Mendes
Lílian Santiago Pinho de
LS
Oliveira
Gil
G
Guerra-Júnior
José Dirceu
JD
Ribeiro
D000293:Adolescent; D001823:Body Composition; D001827:Body Height; D001835:Body Weight; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015430:Weight Gain; D055815:Young Adult
D013006:Growth Hormone